Literature DB >> 25348355

Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface.

Banashree Bondhopadhyay1, Anuradha Moirangthem, Anupam Basu.   

Abstract

Toll-like receptor 3 has been targeted in different cancers for adjuvant therapy. The ligand-mediated effects of TLR-3 on cancer cells are discordant. In the present work, we have addressed the hypothesis possibility of cell membrane-bound action of TLR-3 in breast cancer to justify its pro-tumor effect. TLR-3 was stimulated by Poly (I:C) on the surface of human breast cancer cells MCF-7 and MDA-MB-231 for up to 72 h. To check the cell survival and growth, thiazol blue tetrazolium bromide (MTT) assay, apoptosis assay, and cell cycle analysis were carried out. For changes in the metastatic properties, in vitro colony formation assay, scratch-wound healing assay and adhesion assay were also done. Using real-time PCR and immunocytochemistry, expression of E-cadherin, was studied. To determine the affect of cytoplasmic stimulation, Poly (I:C) was delivered with lipid transfection reagent. The results of the aforesaid experiments showed that there was a gradual increase of cellular survivability, growth, and metastasis after the cell surface stimulation of TLR-3 with Poly (I:C). Interestingly, E-cadherin expression was increased both at transcriptional and translational level. On the other hand, when Poly (I:C) was delivered in the cytoplasm by lipid transfecting medium, the cells survivability was decreased. For the first time, in the present work, we are convincingly reporting the functional evidence that TLR-3 induces cell survivability and metastasis through cell surface. The present work may help for the proper understanding of the adjuvant therapy of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25348355     DOI: 10.1007/s13277-014-2737-8

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  30 in total

1.  Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth.

Authors:  Zhenyu Cai; Amir Sanchez; Zhongcheng Shi; Tingting Zhang; Mingyao Liu; Dekai Zhang
Journal:  Cancer Res       Date:  2011-03-22       Impact factor: 12.701

2.  Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts.

Authors:  Uzma A Hasan; Giorgio Trinchieri; Jaromir Vlach
Journal:  J Biol Chem       Date:  2005-03-23       Impact factor: 5.157

3.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

4.  Toll-like receptor 3-elicited MAPK activation induces stabilization of interferon-β mRNA.

Authors:  Ingvild Bjellmo Johnsen; Thuy Thanh Nguyen; Bjarte Bergstrøm; Egil Lien; Marit Walbye Anthonsen
Journal:  Cytokine       Date:  2011-12-24       Impact factor: 3.861

5.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

Authors:  SaeGwang Park; Zhujun Jiang; Eric D Mortenson; Liufu Deng; Olga Radkevich-Brown; Xuanming Yang; Husain Sattar; Yang Wang; Nicholas K Brown; Mark Greene; Yang Liu; Jie Tang; Shengdian Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

6.  TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance.

Authors:  Weigang He; Qiuyan Liu; Li Wang; Wei Chen; Nan Li; Xuetao Cao
Journal:  Mol Immunol       Date:  2007-02-27       Impact factor: 4.407

7.  Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation.

Authors:  Takashi Ebihara; Masahiro Azuma; Hiroyuki Oshiumi; Jun Kasamatsu; Kazuya Iwabuchi; Kenji Matsumoto; Hirohisa Saito; Tadatsugu Taniguchi; Misako Matsumoto; Tsukasa Seya
Journal:  J Exp Med       Date:  2010-11-08       Impact factor: 14.307

8.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Authors:  Robert Besch; Hendrik Poeck; Tobias Hohenauer; Daniela Senft; Georg Häcker; Carola Berking; Veit Hornung; Stefan Endres; Thomas Ruzicka; Simon Rothenfusser; Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

Review 9.  Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies.

Authors:  Constantin N Baxevanis; Ioannis F Voutsas; Ourania E Tsitsilonis
Journal:  Immunotherapy       Date:  2013-05       Impact factor: 4.196

10.  Polyinosinic-polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors.

Authors:  Shuo Peng; Jianlin Geng; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  Cancer Sci       Date:  2008-12-22       Impact factor: 6.716

View more
  5 in total

Review 1.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

2.  Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma.

Authors:  Louise Soo Yee Tan; Benjamin Wong; Nagaraja Rao Gangodu; Andrea Zhe Ern Lee; Anthony Kian Fong Liou; Kwok Seng Loh; Hao Li; Ming Yann Lim; Andres M Salazar; Chwee Ming Lim
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 3.  Roles of Toll-Like Receptor 3 in Human Tumors.

Authors:  Xin Zheng; Song Li; Hui Yang
Journal:  Front Immunol       Date:  2021-04-27       Impact factor: 7.561

Review 4.  Two Opposing Faces of Retinoic Acid: Induction of Stemness or Induction of Differentiation Depending on Cell-Type.

Authors:  Belén Mezquita; Cristóbal Mezquita
Journal:  Biomolecules       Date:  2019-10-04

5.  Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy.

Authors:  Yinglu Feng; Yongan Chen; Yongbin Meng; Qingxin Cao; Qun Liu; Changquan Ling; Chen Wang
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.